Access Biotechnology and returning investor Eli Lilly were among the participants in a series B round for the RNA-based drug developer.
US-based RNA therapeutics developer DTx Pharma has closed a $100m series B round that included pharmaceutical firm Eli Lilly and Access Biotechnology, a subsidiary of conglomerate Access Industries.
Investment manager RA Capital Management led the round, which included Surveyor Capital, Cormorant Asset Management, Janus Henderson Investors, Logos Capital, Friedman Bioventure Fund, ExSight Ventures and Viva BioInnovator, part of holding company Viva Biotech Holdings.
DTx is working on drugs intended to treat diseases by addressing their genetic drivers. Its Falcon technology…
